Intellia suggests ATTR amyloidosis gene editing treatment has over a year of durability as it gears up for PhIII

Intellia on Thursday presented new results for its gene editing treatment in 65 patients with ATTR amyloidosis — a condition in which …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II